Previously, the study met its pre-specified interim analysis enrollment target of 132 patients ahead of schedule in March 2026 (with an actual enrollment of 133 patients), and completed the full enrollment of 173 patients in June 2026.

This significant milestone marks the official commencement of the clinical development of this innovative drug in the field of rare autoimmune diseases, bringing new therapeutic hope to IgG4-RD patients who face substantial unmet medical needs.

This milestone marks a significant step in providing patients with advanced solid tumors a more convenient and safer treatment option through optimized drug delivery.

Ms. Xiao will oversee the Company’s Investment and Financing Strategy Department, with responsibilities encompassing the Finance Department, Internal Audit Department, and budget management. She will report directly to Dr. Wenzhi Tian, Chairman, Chief Executive Officer, and Chief Scientific Officer of ImmuneOnco.

Recognized for its outstanding innovative R&D capabilities and robust pipeline, this dual recognition not only highlights the industry's high affirmation of ImmuneOnco's technological innovation but also further solidifies the Company's leading position in the biopharmaceutical sector.